BFH772 1% ointment + Vehicle ointment + Noritate® 1% cream
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Erythemato-telangiectatic Rosacea
Conditions
Erythemato-telangiectatic Rosacea
Trial Timeline
Sep 1, 2011 → Feb 1, 2012
NCT ID
NCT01449591About BFH772 1% ointment + Vehicle ointment + Noritate® 1% cream
BFH772 1% ointment + Vehicle ointment + Noritate® 1% cream is a phase 2 stage product being developed by Novartis for Erythemato-telangiectatic Rosacea. The current trial status is completed. This product is registered under clinical trial identifier NCT01449591. Target conditions include Erythemato-telangiectatic Rosacea.
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01449591 | Phase 2 | Completed |